These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 32896015)

  • 1. Synergistic anticancer activity of sorafenib, paclitaxel, and radiation therapy on anaplastic thyroid cancer in vitro and in vivo.
    Kim SY; Kim SM; Chang H; Chang HS; Park CS; Lee YS
    Head Neck; 2020 Dec; 42(12):3678-3684. PubMed ID: 32896015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic Anticancer Activity of
    Yun HJ; Kim HJ; Kim J; Kim SY; Chang HS; Park CS; Chang HJ; Park KC
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33430361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sorafenib and Quinacrine Target Anti-Apoptotic Protein MCL1: A Poor Prognostic Marker in Anaplastic Thyroid Cancer (ATC).
    Abdulghani J; Gokare P; Gallant JN; Dicker D; Whitcomb T; Cooper T; Liao J; Derr J; Liu J; Goldenberg D; Finnberg NK; El-Deiry WS
    Clin Cancer Res; 2016 Dec; 22(24):6192-6203. PubMed ID: 27307592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Krüppel-Like Factor 4 in the Maintenance of Chemoresistance of Anaplastic Thyroid Cancer.
    Lee SI; Kim DK; Seo EJ; Choi EJ; Kwon YW; Jang IH; Lee JC; Kim HY; Shong M; Kim JH; Kim SJ
    Thyroid; 2017 Nov; 27(11):1424-1432. PubMed ID: 28920531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sorafenib inhibits vascular endothelial cell proliferation stimulated by anaplastic thyroid cancer cells regardless of BRAF mutation status.
    Ishihara S; Onoda N; Noda S; Asano Y; Tauchi Y; Morisaki T; Kashiwagi S; Takashima T; Ohira M
    Int J Oncol; 2019 Nov; 55(5):1069-1076. PubMed ID: 31545405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic Activity of N-hydroxy-7-(2-naphthylthio) Heptanomide and Sorafenib Against Cancer Stem Cells, Anaplastic Thyroid Cancer.
    Park KC; Kim SM; Jeon JY; Kim BW; Kim HK; Chang HJ; Lee YS; Kim SY; Choi SH; Park CS; Chang HS
    Neoplasia; 2017 Mar; 19(3):145-153. PubMed ID: 28142087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PLK4 inhibitor exhibits antitumor effect and synergizes sorafenib via arresting cell cycle and inactivating Wnt/β-catenin pathway in anaplastic thyroid cancer.
    Zhu W; Xie B
    Cancer Biol Ther; 2023 Dec; 24(1):2223383. PubMed ID: 37351847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel combination of withaferin A and sorafenib shows synergistic efficacy against both papillary and anaplastic thyroid cancers.
    Cohen SM; Mukerji R; Timmermann BN; Samadi AK; Cohen MS
    Am J Surg; 2012 Dec; 204(6):895-900; discussion 900-1. PubMed ID: 23231932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic inhibition of polo-like kinases in anaplastic thyroid cancer.
    Lin SF; Yeh CN; Huang YT; Chou TC; Wong RJ
    Cancer Sci; 2021 Feb; 112(2):803-814. PubMed ID: 33306266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential of the dual mTOR kinase inhibitor AZD2014 to overcome paclitaxel resistance in anaplastic thyroid carcinoma.
    Milošević Z; Banković J; Dinić J; Tsimplouli C; Sereti E; Dragoj M; Paunović V; Milovanović Z; Stepanović M; Tanić N; Dimas K; Pešić M
    Cell Oncol (Dordr); 2018 Aug; 41(4):409-426. PubMed ID: 29790111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non‑invasive monitoring of paclitaxel and lenvatinib efficacy against anaplastic thyroid cancer in orthotopic SCID mouse models using small‑animal FDG‑PET/CT.
    Aoyama M; Takizawa H; Otani T; Inoue S; Kawakita N; Tsuboi M; Bando Y; Uehara H; Kondo K; Tangoku A
    Oncol Rep; 2020 Oct; 44(4):1709-1716. PubMed ID: 32945510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic Activity of Paclitaxel, Sorafenib, and Radiation Therapy in advanced Renal Cell Carcinoma and Breast Cancer.
    Choi KH; Jeon JY; Lee YE; Kim SW; Kim SY; Yun YJ; Park KC
    Transl Oncol; 2019 Feb; 12(2):381-388. PubMed ID: 30522045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological effects of vinorelbine in combination with lenvatinib in anaplastic thyroid cancer.
    Di Desidero T; Orlandi P; Gentile D; Banchi M; Alì G; Kusmic C; Armanetti P; Cayme GJ; Menichetti L; Fontanini G; Francia G; Bocci G
    Pharmacol Res; 2020 Aug; 158():104920. PubMed ID: 32461187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy of tyrosine kinase inhibitor sorafenib with the HSP90 inhibitor onalespib as a novel treatment regimen for thyroid cancer.
    Mortensen ACL; Berglund H; Hariri M; Papalanis E; Malmberg C; Spiegelberg D
    Sci Rep; 2023 Oct; 13(1):16844. PubMed ID: 37803074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Dihydrotanshinone I on Proliferation and Invasiveness of Paclitaxel-Resistant Anaplastic Thyroid Cancer Cells.
    Allegri L; Capriglione F; Maggisano V; Damante G; Baldan F
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent antitumor activity of novel taxoids in anaplastic thyroid cancer.
    Wang M; Wang C; Feng C; Guo W; Chen H; Liu B; Li E; Liu W; Taouil A; Ojima I; Hou P
    Endocrine; 2022 Feb; 75(2):465-477. PubMed ID: 34591230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of 17-allylamino-17-demethoxygeldanamycin alone or in combination with paclitaxel on anaplastic thyroid carcinoma cells.
    Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
    Endocrine; 2015 Apr; 48(3):886-93. PubMed ID: 25096912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The EPRS-ATF4-COLI pathway axis is a potential target for anaplastic thyroid carcinoma therapy.
    Mi L; Liu J; Zhang Y; Su A; Tang M; Xing Z; He T; Wei T; Li Z; Wu W
    Phytomedicine; 2024 Jul; 129():155670. PubMed ID: 38704915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
    Ito Y; Onoda N; Ito KI; Sugitani I; Takahashi S; Yamaguchi I; Kabu K; Tsukada K
    Thyroid; 2017 Sep; 27(9):1142-1148. PubMed ID: 28635560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Manumycin enhances the cytotoxic effect of paclitaxel on anaplastic thyroid carcinoma cells.
    Yeung SC; Xu G; Pan J; Christgen M; Bamiagis A
    Cancer Res; 2000 Feb; 60(3):650-6. PubMed ID: 10676649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.